GLP1R and thyroid gland carcinoma: It has also been found that long-term injection of GLP-1 receptor agonists exenatide and liraglutide can promote the occurrence of thyroid cancer in rodents by activating the GLP-1 receptor in a dose-dependent manner (Sherman et al., 2018).